â– PHYSIOLOGICAL CORE: Gastric acid (HCl) secretion by parietal cells in the gastric fundus and body is an energy-intensive process mediated by apical H+/K+-ATPase pumps. It is regulated by three pathways.
â– MOTOR RECEPTOR STIMULATIONS:
1. Acetylcholine (ACh): Released from postganglionic vagal neuro-terminals during the cephalic and gastric phases. Binds to Gq-coupled M3 muscarinic receptors on parietal cells, raising intracellular calcium.
2. Gastrin: Secreted by G-cells in the antrum, it binds to Gq-coupled CCK-B (CCK2) receptors on parietal cells, raising intracellular calcium.
3. Histamine: Secreted by enterochromaffin-like (ECL) cells, it binds to Gs-coupled H2 histamine receptors on parietal cells, elevating intracellular cAMP and activating Protein Kinase A (PKA).
4. Synergistic Amplification: Cooperative activation of the cAMP and calcium signaling pathways amplifies HCl secretion.
â– IMMUNOLOGICAL & CYTOKINE SIGNALLING FLUX:
Pathogen exposure or cellular distress triggers antigen-presenting cell activation. This results in the release of pro-inflammatory cytokines (such as IL-1, TNF-alpha, and IL-6) and triggers receptor-mediated cellular chemotaxis.
â– MOLECULAR PATHWAY DYNAMICS:
Intracellular cascades undergo profound modifications, altering secondary transcription levels and receptor presentation on cellular membranes.
[HY-BOARD-1076]
🌟 Dynamic Clinical Key:
Blocking the H2 receptor with Famotidine or Cimetidine blocks the potent histamine-mediated amplification pathway, reducing acid secretion. Proton Pump Inhibitors (such as Omeprazole) act downstream of these receptors, directly inhibiting the H+/K+-ATPase pump to provide potent acid suppression for GERD and peptic ulcer disease. Target specific monoclonal antibodies or immune suppressors to control the hyper-inflammatory cascade. Therapeutic molecules targeting upstream signaling components demonstrate superior efficacy profiles.